Clinical trails planned in 2024.
Contact your provider to learn about combining your current epilepsy treatment with a new antiepileptic drug candidate.
Redefining epilepsy treatment. Improving lives.
Learn more about enrolling your epilepsy patients in our Phase 2 clinical program.
30% of epilepsy population/ unmet medical need. Proof of efficacy with similar results to bumetanide and furosemide (NKCC antagonists) in two pharmacology models.
